FDA update

Stop watch
Biotech

BMS heart drug delayed as risk mitigation program worked out

Bristol Myers has announced that the FDA has extended the decision date for mavacamten, which was nabbed through the $13 billion buyout of MyoKardia.
Annalee Armstrong Nov 19, 2021 8:55am
fda

FDA updates warning on intragastric balloons in wake of deaths

Jun 6, 2018 8:55am